Observation Alone After Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma
Overview
Authors
Affiliations
Objective: Transsphenoidal surgery is the treatment of choice for nonfunctioning pituitary macroadenomas (NFMA). In this study we evaluated the long-term effects of a treatment strategy in which postoperative radiotherapy was not routinely applied to patients with NFMA.
Design: This was a retrospective follow-up study.
Patients: We included 109 consecutive patients (age 56 +/- 13 yr) operated for NFMA between 1992 and 2004.
Results: Radiological imaging revealed a macroadenoma in all patients, with suprasellar extension in 96% and parasellar/infrasellar extension in 36% of cases. Visual field defects were present in 87% of the patients and improved in 84% of these patients after surgery. Only six patients received postoperative radiotherapy. Ten patients died during the follow-up period. Ninety-seven patients could be assessed for tumor regrowth or tumor recurrence after a mean follow-up period of 6.0 +/- 3.7 yr. In nine patients there was evidence for tumor regrowth, and in one patient tumor recurrence was observed. The mean time to tumor growth/recurrence after initial therapy was 6.9 (range 3-12) yr. Follow-up duration was found to be an independent predictor for tumor regrowth.
Conclusion: Transsphenoidal surgery without postoperative radiotherapy is an effective and safe treatment strategy for NFMA, without evidence for tumor regrowth in 90% of all patients, at least for the duration of follow-up presented in this study. Additional studies are required to exclude higher regrowth and recurrence rates during prolongation of the duration of follow-up.
Lenga P, Grutza M, Kuhlwein D, Walter J, Krieg S, Beynon C Acta Neurochir (Wien). 2024; 166(1):510.
PMID: 39731604 PMC: 11682009. DOI: 10.1007/s00701-024-06401-7.
Bioletto F, Sibilla M, Gasco V, Ghigo E, Grottoli S J Endocrinol Invest. 2024; 47(9):2143-2155.
PMID: 38503992 PMC: 11369010. DOI: 10.1007/s40618-024-02356-9.
Demura M, Sasagawa Y, Hayashi Y, Tachibana O, Nakada M Surg Neurol Int. 2024; 15:70.
PMID: 38468671 PMC: 10927194. DOI: 10.25259/SNI_909_2023.
Katamadze N, Tskaeva A, Pigarova E, Dzeranova L, Tarbaeva N Probl Endokrinol (Mosk). 2024; 69(6):54-62.
PMID: 38311995 PMC: 10851037. DOI: 10.14341/probl13311.
Incidental versus symptomatic nonfunctioning pituitary adenomas: Are they different?.
Guerreiro V, Mendonca F, Ferreira H, Freitas P, Pereira J, Bernardes I Endocrinol Diabetes Metab. 2023; 6(6):e445.
PMID: 37697708 PMC: 10638623. DOI: 10.1002/edm2.445.